Title Loaded From File
8 cases per facility over a 13-year period. We selected 34 of the 239 soft tissue sarcomas reported to the NCDB that are commonly encountered by orthopedic oncologists. We selected only those histologic entities that included a minimum of 50 distinct cases. These 34 soft tissue sarcomas were extracted from the NCDB using the appropriate second and third editions of the WHO International Classification of Disease for Oncology (ICD-0-2/3) site (C40.0-C40.9, C41.0-C41.9) and histology codes. Data were abstracted using coding guidelines documented in the Registry Operations and Data Standards manual for cases diagnosed before 2003 and the Facility Oncology Registry Data Standards manual for diagnosis year 2003 and beyond. The 1998�C2010 annual reports to http://www.selleckchem.com/products/g007-lk.html the NCDB included 63,714 cases of soft tissue sarcomas with the 34 histologies listed in the data tables. The most common soft tissue sarcoma in our report is malignant fibrous histiocytoma (MFH), which includes 12,754 cases over a 13-year period. MFH is followed by Sarcoma NOS (not otherwise specified) and Myxoid Liposarcoma, which occurred at frequencies of 7842 cases and 3996 cases, respectively. Data analyzed include patient gender, age (Note: the ��PUF program only shared compound screening assay data on patients of at least 18 years of age), race, date of initial diagnosis by year, anatomic site of primary tumor, tumor grade (well differentiated, moderately differentiated, poorly differentiated, undifferentiated), tumor size, and 2-year and 5-year survivorship. Anatomic site coding is divided into 19 anatomical sites, including varying locations within the peripheral and autonomic nervous system, connective and soft tissue lesions, and overlapping lesions within multiple anatomic locations (Tables S1�CS3). Survival rates were calculated for each of the 34 histologic types of soft tissue sarcoma. Descriptive statistics were generated for all measures, including means, ranges, and standard deviations for continuous measures and frequencies and proportions for categorical data. Overall survival (OS) was calculated from the date of diagnosis to the last known date of follow-up or the date of death. Sarcoma-specific death was not reported. Estimates of survival were calculated by using RVX-208 the Kaplan�CMeier (product-limit) method and the log-rank test was used to assess statistical significance. Cox proportional hazards models were fit to assess survival differences adjusting for demographic and clinical covariates. Statistical significance was defined as P
